# 1. Financial Performance ## A. Key Figures * Revenue: ₹104.9 Cr (+5%) · EBITDA: ₹20.6 Cr (+22%) (19.6% margin) * **PAT:** ₹13.4 Cr (+20%) (12.8% margin) · **EPS:** ₹7.4 (+20%) * **Total Assets:** ₹70 Cr (+71%) · **Equity & Reserves:** ₹11 Cr (+59%) * Cash & Cash Equivalents: ₹1.9 Cr (-47%) · Net Cash from Operations: ₹7.1 Cr (-50%) ## B. Revenue Growth * **Record Top-Line Performance:** Revenue reached an all-time high, driven by strong demand and a **robust, integrated business model** enabling scalability. * **Cost Discipline:** Materials cost declined **2%**, supporting margin resilience despite rising employee expenses. * **Expense Pressures:** Staffing costs surged **25%**, reflecting strategic hiring and operational ramp-up. * **Other Income Surge:** Non-operating income more than doubled (+160%), contributing to bottom-line strength. ## C. Profit Margins * **Margin Expansion:** EBITDA and PAT margins improved meaningfully, signaling **strong operational leverage** and cost optimization. * **Financial De-leveraging:** Finance costs eliminated entirely, enhancing pre-tax profitability. * **Depreciation Uptick:** Higher depreciation (+52%) reflects continued asset base expansion and capacity investment. ## D. Balance Sheet * **Asset Growth & Reinvestment:** Total assets expanded **71%**, led by working capital build-up—**inventories +142%** and **receivables +104%**—indicating scaling operations. * **Strengthened Equity Base:** Equity and reserves grew **59%**, reducing reliance on debt. * **Debt Reduction:** Borrowings down **34%**, signaling proactive balance sheet deleveraging. * **Liquidity Tightening:** Sharp decline in cash reserves (-47%) aligns with aggressive reinvestment and working capital absorption. ## E. Cash Flow * **Operating Cash Flow Deterioration:** Despite strong profits, cash generation halved due to **significant working capital outflows**, especially in receivables and inventories. * **Financing Outflows Eased:** Net cash used in financing activities fell **81%**, as repayment pressures moderated. * **Investing Activity Stable:** Capital expenditure slightly reduced, with new outflows in other investments signaling strategic deployment. * **Cash Position Under Pressure:** Ending cash declined sharply, with full-year **net cash outflow of ₹7 Cr**, highlighting near-term liquidity demands. --- # 2. Product & Portfolio Expansion ## A. Key Figures * **Product Portfolio:** **3,559** products in FY25 (+6%) ## B. Product Count Growth * **Diversified Science-Backed Portfolio:** Broad and expanding range of **3,500+ developed products** across nutraceuticals, cosmetics, pet care, and homecare, underpinned by a 22+ year CDMO legacy. * **Brand-Focused CDMO Model:** Influx Healthtech positions as a formulation-driven, brand-centric partner with end-to-end capabilities from development to manufacturing. ## C. New Launches * **Sustained Innovation Pipeline:** Multi-year rollout of novel formats including gummies, effervescent tablets, vegan bars, and pet care products, with **pet food expansion** (dog kibbles live, cat food upcoming) targeting India’s **$5 billion pet market**. * **Future-Ready Product Roadmap:** Active development in **ayurvedic gummies**, **oral dissolving powders**, **pet nutrition toppers**, and **popped chips**, signaling focus on functional and convenience-driven wellness. ## D. F&D Capabilities * **Dedicated In-House Innovation Engine:** An **8-member F&D team** drives formulation design, optimization, and commercialization, enabling rapid response to client and market needs. * **Strategic Development Partner:** Evolving beyond manufacturing to offer integrated R&D services, supported by digital and D2C capability upgrades to enhance consumer engagement. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Capacity Utilization:** **93%** Unit-1 Nutraceuticals · **90%** Unit-2 Cosmetics & Ayurvedic · **66%** Unit-3 Pet Supplements & Homecare * **IPO Capital Allocation:** **₹23 Cr** for nutraceutical facility (3,204 m²) · **₹12 Cr** for veterinary food facility (1,350 m²) · **₹3 Cr** for homecare/cosmetics machinery * **Throughput Expansion:** **1,230 kg/day** tablet capacity · **48,000 bottles/shift** (liquid) · **98,000 sachets/shift** (sachet) ## B. Facility Utilization * **High Utilization in Core Units:** Unit-1 and Unit-2 operating near full capacity, reflecting strong demand and efficient asset deployment. * **Scalable Underutilized Unit:** Unit-3 shows significant headroom for volume ramp-up at current 66% utilization. ## C. Capacity Expansion * **Strategic Capacity Buildout:** Multi-divisional expansion underway to meet demand, targeting a **5x increase** in total manufacturing capacity post-IPO. * **Enhanced Throughput:** Doubled liquid and sachet output per shift, alongside expanded tablet capacity, enabling higher operational efficiency. ## D. Quality Certifications * **Comprehensive Regulatory Compliance:** Three Palghar facilities hold **GMP, HACCP, ISO 22000:2018, NSF, FDA registration**, and other leading certifications, supporting global market access. * **Third-Party Validation:** Recognized as **Best Sports Supplement Manufacturer 2016 (Western India)** and awarded **Grade A+ Exemplar Certification in 2025**, underscoring quality leadership. --- # 4. Client & Geography Mix ## A. Client Diversity * **Headline:** Broad and diversified client base spans multinational corporations, high-growth D2C brands, and niche healthcare providers across cosmetics, pharmaceuticals, and homecare sectors. * **Headline:** Strong market reach evidenced by marquee clients and multi-geography presence, reducing concentration risk and supporting stable demand. * **Headline:** Client acquisition and engagement driven by targeted marketing, exhibitions, and delivery of high-quality, bespoke solutions fostering long-term partnerships. ## B. Global Reach * **Headline:** Strategic expansion into new geographies supported by Halal certification, enhancing access to religiously sensitive markets and building consumer trust. --- # 5. Innovation & Trends ## A. Key Figures * **India Nutraceutical Market Opportunity:** **$76 Bn** potential * **CDMO Industry Growth:** India growing at **twice the rate** of global CDMO industry ## B. Formulation Innovation * **Future-Ready Pipeline:** Strategic focus on **advanced formulation development** in nutraceuticals, cosmetics, pet care, and homecare to capture evolving consumer trends. * **Innovation-Led Differentiation:** **Diversified portfolio** strengthened by in-house R&D, enabling tailored, market-ready solutions and enhanced client value. * **Recognition & Relevance:** Past accolades and ongoing refinement for **cost efficiency and feasibility** underscore technical credibility and commercial alignment. ## C. Market Alignment * **Structural Tailwinds:** Indian CDMO sector benefits from global outsourcing shift, **patent expiries**, and rising demand for generics, positioning India as a preferred low-cost innovation hub. * **Robust Demand Drivers:** **Rising health consciousness** and lifestyle shifts are fueling strong momentum in the domestic nutraceutical market. * **Strategic Expansion:** CDMOs scaling capabilities in **early-stage R&D** and **clinical trial materials**, aligning with India’s growing role in global drug development. --- # 6. Risks & Compliance ## A. Regulatory Risk * **Compliance as Growth Enabler:** Regulatory adherence legally enables U.S. market access and strengthens positioning in global markets. * **Policy Tailwinds:** Supportive FSSAI regulations and government policies enhance product quality, consumer trust, and sector expansion. ## B. Operational Risk * **Certifications Drive Trust & Quality:** Industry-leading compliance systems ensure product safety, prevent contamination, and support revenue growth through enhanced customer and regulator confidence. * **Sustainability Reinforces Reputation:** Certifications underscore commitment to eco-friendly practices, strengthening brand equity and regulatory alignment. * **Independent Oversight with Domain Expertise:** Independent Directors bring deep domain and financial expertise—**Dr. Vipul Patel** (26+ years, MD Pathology) oversees operational risk and strategic initiatives, while **Mr. Ashok Kumar Jain** (30+ years, ICAI) ensures financial integrity and compliance.